Skip to main content
48 search results for:

Leflunomide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 22-07-2022 | Lupus nephritis | News | Article

    Leflunomide shows promise in lupus nephritis

    Leflunomide, a DMARD used in the treatment of rheumatoid arthritis, is noninferior to azathioprine for the prevention of kidney flares in people with lupus nephritis, Chinese researchers report.

  2. 04-03-2022 | Psoriatic arthritis | News | Article

    COMPLETE-PsA: Adding leflunomide to methotrexate may improve outcomes

    The addition of leflunomide to methotrexate monotherapy results in significant improvements in disease activity among people with active psoriatic arthritis, suggest findings from the COMPLETE-PsA trial.

  3. 16-03-2021 | Rheumatoid arthritis | News | Article

    AMARA: Adding rituximab to leflunomide may improve some outcomes for RA patients

    Add-on rituximab treatment may improve some clinical outcomes for patients with rheumatoid arthritis and an inadequate response to leflunomide, suggest findings from the AMARA trial.

  4. 06-04-2020 | Sjögren’s syndrome | News | Article

    Support for further study of leflunomide–hydroxychloroquine for primary Sjögren’s syndrome

    Findings from RepurpSS-I, a small phase 2a trial, suggest that leflunomide–hydroxychloroquine combination therapy has a favorable safety profile and gives rise to a clinical response in patients with primary Sjögren’s syndrome.

  5. 11-08-2017 | Rheumatoid arthritis | News | Article
    News in brief

    Equivalent efficacy of leflunomide and low-dose rituximab shown in RA

    Results of a Sri Lankan trial suggest that leflunomide and low-dose rituximab have comparable efficacy when used in combination with methotrexate for the treatment of patients with rheumatoid arthritis refractory to first-line non-biologic disease modifying antirheumatic drugs.

  6. 01-03-2021 | COVID-19 | Feature | Article

    COVID-19 vaccination in patients with rheumatic diseases

    For many of the drugs – including TNF inhibitors, interleukin inhibitors, low-dose glucocorticoids (prednisone-equivalent dose <20 mg/day), sulfasalazine, hydroxychloroquine, and leflunomide – no modifications to either immunomodulatory therapy or vaccination timing are recommended.

  7. 12-10-2021 | COVID-19 | News | Article
    News in brief

    EULAR updates guidance on immunomodulatory treatment for COVID-19

    However, there was insufficient evidence to recommend the use of other immunomodulatory drugs, including interferon inhibitors, leflunomide, or cyclosporin, and they say that further research into biomarker-based stratification is needed for interleukin-1 inhibitors such as anakinra.

  8. 14-05-2021 | Psoriatic arthritis | News | Article

    Early data do not show fecal microbiota transplantation benefit in peripheral PsA

    Within 26 weeks of undergoing FMT or sham transplantation, a respective 60% and 19% of patients experienced treatment failure, defined as needing more than one intra-articular glucocorticoid injection or a biologic or non-methotrexate conventional DMARD (leflunomide, sulfasalazin, or ciclosporin).

  9. 11-11-2020 | ACR 2020 | Conference coverage | Article

    Survey sheds light on rheumatology provider experiences during COVID-19 pandemic

    However, 66% said they would withhold methotrexate or leflunomide and 52% would withhold glucocorticoids of 20 mg/day or higher for 2 weeks or less if a live vaccine was available; and higher proportions would withhold tumor necrosis factor (TNF) inhibitors (85%), anti-IL-17/23 biologics (82%), Janus kinase inhibitors (78%), belimumab (77%), non-TNF biologics (76%), and immunosuppressive drugs such as azathioprine (64%) for a period of 3 to 8 weeks.

  10. 31-03-2020 | Rheumatoid arthritis | News | Article

    Support for combining non-methotrexate csDMARDs with biologics in RA patients

    In the three studies where leflunomide was the alternative csDMARD, leflunomide use was associated with a significant 38% higher chance of achieving a good EULAR response.

  11. 06-04-2018 | Spondyloarthropathies | Feature | Article
    Updated April 2021

    At a glance: Trials of tofacitinib in spondyloarthritis

    OPAL Broaden: PsA Phase 3 Patient population: Active PsA and an inadequate response to conventional DMARDs Treatment groups: Tofacitinib 5 mg or 10 mg twice daily, adalimumab, or placebo, all given alongside a stable dose of a single conventional DMARD (methotrexate, sulfasalazine, or leflunomide) Status: Published https://clinicaltrials.gov/show/NCT01877668 The findings from OPAL Broaden, published in The New England Journal of Medicine in October 2017, showed that patients treated with tofacitinib 5 mg or 10 mg were significantly more likely to achieve at least a 20% improvement in ACR criteria (ACR20) after 3 months of treatment than placebo-treated patients, with corresponding rates of 50% and 61% versus 33%.

  12. 08-01-2020 | Rheumatoid arthritis | News | Article

    Optimal management mitigates RA pregnancy risks

    The authors defined the ideal pathway as according to the presence of three indicators: diagnosis with laboratory blood tests, musculoskeletal imaging, and tests for antiphospholipid, extractable nuclear antigen, and antinuclear antibodies; treatment based on no exposure or wash-out from methotrexate and leflunomide, and no exposure to biologic drugs from conception to delivery; and  prenatal follow-up with at least one visit to a rheumatologist.

  13. 11-02-2020 | Rheumatoid arthritis | News | Article

    Reduced bone density loss with b/tsDMARDs vs csDMARDs in RA

    The csDMARDs included methotrexate, sulfasalazine, hydroxychloroquine, azathioprine, and leflunomide.

  14. 01-10-2019 | TNF inhibitors | News | Article

    Methotrexate use associated with lower rates of TNF inhibitor discontinuation

    The researchers found less clear associations for the other conventional DMARDs used; sulfasalazine was associated with lower rates of TNF inhibitor discontinuation in people with RA or PsA, while hydroxychloroquine use was associated with lower discontinuation rates only in those with RA, and there was no link between leflunomide use and discontinuation rates for any of the patient groups.

  15. 07-06-2019 | Rheumatoid arthritis | Case study | Article

    Tofacitinib in a patient with refractory severe rheumatoid arthritis

    In 2001 she was treated with leflunomide, with an initial good response, but by 2003 she developed severely active disease despite 20 mg leflunomide and 15 mg oral prednisolone daily.

  16. 05-09-2019 | Juvenile idiopathic arthritis | News | Article

    Pregnancy outcomes largely unaffected by DMARD exposure at conception in JIA

    “Notably, approximately every fifth DMARD-exposed pregnancy was electively terminated, including every fourth pregnancy in DMARD-exposed women and every second pregnancy in [methotrexate]- or [leflunomide]-exposed women,” say Kristen Minden (German Rheumatism Research Center, Berlin) and study co-authors in Rheumatology .

  17. 10-06-2019 | Psoriatic arthritis | Feature | Article

    A closer look at guidelines for the management of PsA

    Indeed, for treatment-naïve patients with active PsA, the guidelines recommend first-line treatment with a TNF inhibitor over methotrexate, sulfasalazine, leflunomide, cyclosporine, and apremilast.

  18. 10-07-2019 | Psoriatic arthritis | Highlight | Article

    Methotrexate versus etanercept as first-line therapy for psoriatic arthritis

    The case for etanercept as first-line therapy in PsA Author: William Tillett The recent ACR/NPF guidelines recommend TNF inhibitor therapy over oral small molecule therapy (sulfasalazine, methotrexate, leflunomide, apremilast) for treatment-naïve patients with PsA on the basis of efficacy, and in the absence of contraindications such as infections, congestive cardiac failure, or demyelinating disease.

  19. 01-02-2019 | Psoriatic arthritis | News | Article

    Unclear benefits of methotrexate highlighted for PsA patients

    They note that at present, “[w]ith the exception of leflunomide, head-to-head data are inadequate to inform comparison [of methotrexate] versus other DMARDs, including biologic DMARDs.”

  20. 23-01-2019 | Rheumatoid arthritis | News | Article

    Hydroxychloroquine may benefit some RA patients if combined with other drugs

    One trial compared hydroxychloroquine plus sulfasalazine with sulfasalazine alone, and another compared hydroxychloroquine plus leflunomide with leflunomide alone.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.